Direct effects of doxorubicin on skeletal muscle contribute to fatigue (British Journal of Cancer (2009) 100, (311-314) DOI: 10.1038/sj.bjc.6604858);Direct effects of doxorubicin on skeletal muscle contribute to fatigue

British Journal of Cancer

Volumn 100, Issue 2, 2009, Pages 311-314

  Van Norren, K ^a   Van Helvoort, A ^a   Argiles J M ^b   Van Tuijl, S ^a   Arts, Karin ^a   Gorselink, M ^a   Laviano, A ^c   Kegler, D ^a   Haagsman, H P ^d   Van Der Beek, E M ^a  

^a DANONE RESEARCH   (Netherlands)

^b UNIVERSITY OF BARCELONA   (Spain)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Animal models; Chemotherapy; Quality of life

Indexed keywords

CALCIUM; DOXORUBICIN;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; IN VITRO STUDY; MALE; MOUSE; MUSCLE CONTRACTION; MUSCLE FATIGUE; MUSCLE FUNCTION; MUSCLE RELAXATION; MYOTUBE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SKELETAL MUSCLE; TIME;

EID: 58749103330     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604992     Document Type: Erratum

References (17)

1. Abramson JJ, Buck E, Salama G, Casida JE, Pessah IN (1988) Mechanism of anthraquinone-induced calcium release from skeletal muscle sarcoplasmic reticulum. J Biol Chem 263: 18750-18758
2. Awasthi S, Singhal SS, Awasthi YC, Martin B, Woo JH, Cunningham CC, Frankel AE (2008) RLIP76 and Cancer. Clin Cancer Res 14: 4372-4377
3. De Beer EL, Finkle H, Voest EE, Van Heijst BG, Schiereck P (1992) Doxorubicin interacts directly with skinned single skeletal muscle fibres. Eur J Pharmacol 214: 97-100
4. Delgado G, Potkul RK, Treat JA, Lewandowski GS, Barter JF, Forst D, Rahman A (1989) A phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer. Am J Obstet Gynecol 160: 812-817
5. Gorselink M, Vaessen SF, van der Flier LG, Leenders I, Kegler D, Caldenhoven E, van der Beek E, van Helvoort A (2006) Mass-dependent decline of skeletal muscle function in cancer cachexia. Muscle Nerve 33: 691-693
6. Higdon ML, Higdon JA (2006) Treatment of oncologic emergencies. Am Fam Physician 74: 1873-1880
7. Hortobagyi GN (1997) Anthracyclines in the treatment of cancer. An overview. Drugs 54: 1-7
8. Ishikawa T, Zhu BL, Maeda H (2006) Effects of therapeutic agents on cellular respiration as an indication of metabolic activity. Hum Exp Toxicol 25: 135-140
9. Jensen RA (1986) Doxorubicin cardiotoxicity: contractile changes after long-term treatment in the rat. J Pharmacol Exp Ther 236: 197-203
10. Kelly GS (1998) Clinical applications of N-acetylcysteine. Altern Med Rev 3: 114-127
11. Krause MS, Oliveira Jr LP, Silveira EM, Vianna DR, Rossato JS, Almeida BS, Rodrigues MF, Fernandes AJ, Costa JA, Curi R, de Bittencourt Jr PI (2007) MRP1/GS-X pump ATPase expression: is this the explanation for the cytoprotection of the heart against oxidative stress-induced redox imbalance in comparison to skeletal muscle cells? Cell Biochem Funct 25: 23-32
12. Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA (2003) Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 108: 2423-2429
13. MacLennan DH (2000) Ca2+ signalling and muscle disease. Eur J Biochem 267: 5291-5297
14. Morrow GR, Andrews PL, Hickok JT, Roscoe JA, Matteson S (2002) Fatigue associated with cancer and its treatment. Support Care Cancer 10: 389-398
15. Pan Y, Zvaritch E, Tupling AR, Rice WJ, de Leon S, Rudnicki M, McKerlie C, Banwell BL, MacLennan DH (2003) Targeted disruption of the ATP2A1 gene encoding the sarco(endo)plasmic reticulum Ca2+ ATPase isoform 1 (SERCA1) impairs diaphragm function and is lethal in neonatal mice. J Biol Chem 278: 13367-13375
16. Singal PK, Iliskovic N, Li T, Kumar D (1997) Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 11: 931-936
17. Wallace KB (2007) Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol 7: 101-107